WHO-UMC IDMP Management and Publish API, published by Uppsala Monitoring Centre. This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/Uppsala-Monitoring-Centre/WHO-UMC-IDMP-Service/ and changes regularly. See the Directory of published versions
Generated Narrative: MedicinalProductDefinition 1A0661AE2A40
version: 1; Last updated: 2019-05-22 00:52:27+0000;
Information Source: http://idmp.who-umc.org/fhir
identifier: http://who-umc.org/idmp/CodeSystem/product
/1A0661AE2A40, https://health-products.canada.ca/dpd-bdpp
/02182750
type: Medicinal Product
domain: Human use
status: Active
combinedPharmaceuticalDoseForm: TABLETS
classification: 91B3CA582581F57E4092F13AAF476215
Type | Contact |
Proposed Marketing Authorization Holder/Person | Auro Pharma Inc |
code: WHODrug DrugCode 00113802216: 00113802216
name
productName: Auro methotrexate
Usages
Country Jurisdiction Language Canada Canada English
Generated Narrative: Organization #auropharmainc
name: Auro Pharma Inc